Last reviewed · How we verify
NCT00070161
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Phase 2 trial testing EGb761 in Brain and Central Nervous System Tumors in 68 participants. Completed in 1 August 2012.
1 May 2005
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 68 |
| Start date | 1 July 2001 |
| Primary completion | 1 May 2005 |
| Estimated completion | 1 August 2012 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- EGb761 — full drug profile →
- donepezil hydrochloride — full drug profile →
- cognitive assessment
Conditions studied
- Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →
- Radiation Toxicity — all drugs for Radiation Toxicity →
Sponsor
Wake Forest University Health Sciences
Who can join
Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors or Radiation Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00070161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain and Central Nervous System Tumors
Currently open trials in the same condition.
- NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00070161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 9 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00070161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing